TSXV:RXPharmaceuticals
BioSyent (TSXV:RX) TTM EPS Growth Outpaces Five Year Trend Challenging Valuation Skeptics
BioSyent (TSXV:RX) has wrapped up FY 2025 with fourth quarter revenue of CA$9.7 million and basic EPS of CA$0.18, supported by trailing 12 month revenue of CA$43.1 million and EPS of CA$0.80 that frame the latest numbers in a fuller context. Over recent periods the company has seen quarterly revenue move from CA$8.8 million in Q4 2024 to CA$9.7 million in Q4 2025, while basic EPS shifted from CA$0.14 to CA$0.18, and trailing 12 month EPS moved from CA$0.63 to CA$0.80 alongside revenue rising...